A Study in Recurrent Glioblastoma (GB)
The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer
Glioblastoma
DRUG: LY2157299 monohydrate|DRUG: Lomustine|DRUG: Placebo
Overall survival, Date of randomization to date of death from any cause estimated up to 2 years
Population Pharmacokinetics (PK): median population clearance, Cycle 1, Day 1, 3, 14, 15 and 16|Progression free survival (PFS), Randomization to the date of objective progression or death from any cause estimated up to 2 years|Percentage of Participants with Tumor Response, Every 2 cycles to disease progression or participant starts a new anticancer therapy estimated up to 2 years|Change from baseline in neurocognitive function, Baseline, cycle 1, cycle 2 then every 2 cycles to 30 day post discontinuation follow up estimated up to 2 years|Population Pharmacokinetics (PK): absorption, Cycle 1, Day 1, 3, 14, 15 and 16|Population Pharmacokinetics (PK): volume of distribution, Cycle 1, Day 1, 3, 14, 15 and 16|Change from baseline in MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) score, Baseline, cycle 1, cycle 2 then every 2 cycles to 30 day post discontinuation follow up estimated up to 2 years
The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer